Immuron Ltd has released a press release.
North American Travelan sales up 98% to Dec 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea
- Immuron Receives AUD $0.53M R&D Tax Concession Refund
- Immuron North American Q1 Sales Up 111% YoY
- US Defense funds AU$5.5M for Immuron New Gastro Weapon
- US Defense Reports Immuron Travelan Targets Cholera
Later from Immuron
- Resignation of Managing Director and cuts amid Covid19
- Immuron Global Sales Up 60%
- Response to ASX Price Query
- IMC & CSIRO to produce oral therapeutic for DoD evaluation
- US DoD Receives FDA Guidance on clinical development plans
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron